Objective. - To assess involvement of p53 mutations in development of pancreatic endocrine tumors. Design. - Survey of sporadic pancreatic endocrine tumors. Setting. - Hospital referral centers, mainly in the Los Angeles, Calif, area. Patients. - We obtained fresh surgical specimens from 25 patients (convenience sample) with no family history of endocrine tumors and no evidence of multiple endocrine neoplasia 1 or yon Hippel-Lindau disease. Preoperative tests included serum peptide analysis. Main Outcome Measures. - DNA was prepared from tumor specimens. We screened exons 5 through 8 of the p53 gene using single-strand conformation polymorphism analysis, followed by DNA sequencing when a variant was detected. Results. - A three-base deletion mutation (codon 239) was found in one malignant tumor secreting vasoactive intestinal peptide. Conclusions. - p53 appears to have a limited role in development of pancreatic endocrine tumors. However, evidence from one of our patients suggests it may be involved in tumor progression in uncommon cases.
|Original language||English (US)|
|Number of pages||4|
|Journal||Archives of Pathology and Laboratory Medicine|
|State||Published - 1997|
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Medical Laboratory Technology